Lupus最新文献

{"title":"Factors associated with changes in self-efficacy in patients with systemic lupus erythematosus. Data from the almenara lupus cohort.","authors":"Alvaro M Ñaña-Cordova, Zulema Mamani-Condori, Itala Jordan-Beisaga, Valeria L Reyna-Ruiz, Rocío V Gamboa-Cardenas, Victor Pimentel-Quiroz, Cristina Reátegui-Sokolova, Samira García-Hirsh, Zoila Rodriguez-Bellido, Cesar Pastor-Asurza, Risto Perich-Campos, Graciela S Alarcón, Manuel F Ugarte-Gil","doi":"10.1177/09612033261449978","DOIUrl":"10.1177/09612033261449978","url":null,"abstract":"<p><p>AimTo evaluate the factors associated with changes in self-efficacy in systemic lupus erythematosus (SLE) patients from a prevalent cohort.MethodsMembers of the Almenara Lupus Cohort who had entered it between 2018 and 2024 were included. Sociodemographic variables were collected. Self-efficacy was examined with the five domains of the PROMIS self-efficacy for the management of chronic conditions' instrument and general self-efficacy. The Short Form (SF)-36 health questionnaire' [physical and mental component summary measures (PCS and MCS)] was obtained. Disease activity was ascertained with the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and damage with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Therapeutic variables included the use of antimalarials and of immunosuppressants as well as the daily prednisone dose. Generalized estimating equations were performed using general self-efficacy and the five domains for chronic disease management as outcomes.Results331 patients were included; their mean age at diagnosis was 35.1 (SD = 13.7) years and 91.5% their disease duration at baseline was 10.3 (SD = 7.49) years; (<i>n</i> = 303) were women; 97.9% were Mestizo. Factors associated with a better general self-efficacy were White ethnicity (β = 7.09, SE = 1.14, <i>p</i> < 0.001), being currently employed (β = 1.09, SE = 0.53, <i>p</i> = 0.038), PCS (β = 0.08, SE = 0.02, <i>p</i> < 0.001), and previous general self-efficacy (β = 0.39, SE = 0.05, <i>p</i> < 0.001). In contrast, Black ethnicity (β = -2.06, SE = 0.56, <i>p</i> < 0.001 and daily prednisone dose (β = -0.13, SE = 0.02, <i>p</i> < 0.001) were negatively associated with general self-efficacy.ConclusionsFactors associated with general self-efficacy improvement were higher previous self-efficacy, White ethnicity, being currently employed and having a better HRQoL In contrast, Black ethnicity and higher daily prednisone dose predisposed to general self-efficacy worsening.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"899-909"},"PeriodicalIF":1.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A quality improvement project to incorporate the mycophenolate Risk Evaluation and Mitigation Strategies in an academic lupus clinic.","authors":"Dahima Cintron, Caitlan Pinotti, Jennifer L Rogers, Kai Sun, Rebecca Sadun, Mithu Maheswaranathan, Jayanth Doss, Lisa Criscione-Schreiber, Megan E B Clowse","doi":"10.1177/09612033261458437","DOIUrl":"10.1177/09612033261458437","url":null,"abstract":"<p><p>Background/PurposeMycophenolate compound (MMF, to represent both mycophenolate mofetil and mycophenolic acid) is an immunosuppressant used to treat Systemic Lupus Erythematosus (SLE). Due to its teratogenicity, the FDA recommends universal mycophenolate Risk Evaluation and Mitigations Strategies (MREMS) to prevent unplanned pregnancies and minimize fetal exposure. This quality improvement initiative aimed to improve documentation of the MREMS protocol in the encounter clinic note from 0% to 75% within 14 months.MethodsThe project was conducted in an academic lupus clinic from February 2023 to May 2024, with the intervention beginning in March 2023. MREMS was recommended for adult female SLE patients aged 18-50 on MMF, excluding those with hysterectomy. Interventions included provider and nurse education, nursing algorithms for identifying eligible patients and ordering pregnancy tests, electronic health record template updates, and regular feedback. Required documentation included counseling on MMF teratogenicity and contraception, with pregnancy testing at each visit. Control charts monitored documentation of MREMS counseling and pregnancy testing, and a one-year post-implementation follow-up was completed.ResultsAmong eligible encounters (<i>n</i> = 89), MREMS documentation increased from 0% to an average of 24% during the first 8 months of PDSA cycles, then shifted to an average of 67% of encounters. We reached and sustained our documentation goal of 75% for the last three consecutive months. Pregnancy-test ordering rose from 0% to 63%, and contraception was documented at 98% of visits. Over the course of the intervention, no pregnancies were exposed to MMF. MREMS documentation and pregnancy screening remained above 75% of encounters 1 year after intervention.ConclusionUsing quality improvement cycles, we incorporated a two-part MREMS protocol into a busy academic lupus clinic, with improved documentation and pregnancy screening.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"956-964"},"PeriodicalIF":1.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148157255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Linear/arciform blaschkoid lupus erythematosus tumidus of the face - An extremely rare clinical manifestation.","authors":"Thilo Gambichler, Ocko Kautz, Manuela Krokowski, Ulrika Schade, Stefanie Boms","doi":"10.1177/09612033261452912","DOIUrl":"10.1177/09612033261452912","url":null,"abstract":"","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"992-994"},"PeriodicalIF":1.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148016305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nationwide analysis of childhood-onset systemic lupus erythematosus mortality in Mexico, 2000-2023.","authors":"Ivet Etchegaray-Morales, Claudia Mendoza-Pinto, Pamela Munguía-Realpozo, Diana Molina-Vélez, Juan Eugenio Hernández-Ávila, Edith Ramírez-Lara, Alfonso Ragnar Torres-Jiménez, Ángel David Osorio-Peña, Socorro Méndez-Martínez","doi":"10.1177/09612033261445759","DOIUrl":"10.1177/09612033261445759","url":null,"abstract":"<p><p>ObjectiveTo evaluate national and regional trends in age-standardized mortality rates (ASMRs) from childhood-onset systemic lupus erythematosus (cSLE) in Mexico between 2000 and 2023, stratified by sex and region.MethodsThis cross-sectional, retrospective study used the INEGI national death registry via the Public Health Intelligence Unit (UISP-INSP). Deaths in children aged 1-14 years attributed to cSLE were identified using ICD-10 codes M32.1, M32.8, and M32.9, excluding M32.0. ASMRs per 100,000 population were calculated using the 2010 Mexican census as a reference. Trends by year, sex, and region were analyzed using Poisson regression models with log link and population offset. Incidence rate ratios (IRRs) with 95% confidence intervals were estimated.ResultsFrom 2000 to 2023, 637 cSLE deaths were recorded among 280,334 child deaths. Females accounted for 80.4% (ASMR 0.13; 95% CI 0.12-0.15), nearly fourfold higher than males (0.03; 95% CI 0.03-0.04). Although the Central and Midwest regions concentrated over 60% of total deaths, ASMRs were similar across regions (range 0.08-0.09 per 100,000). No consistent temporal trend in mortality was observed. Poisson regression confirmed significantly lower mortality in boys compared to girls (IRR 0.24; 95% CI 0.19-0.29; <i>p</i> < 0.001) with no statistically significant regional differences.ConclusionscSLE mortality in Mexico has remained stable over time, with a marked female predominance. The regional distribution of deaths likely reflects population density rather than major differences in mortality risk. Strengthening early diagnosis, paediatric rheumatology care networks, and national surveillance systems is essential to reduce disease burden.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"965-971"},"PeriodicalIF":1.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147775511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative study of adverse drug reactions associated with anifrolumab and belimumab for the treatment of systemic lupus erythematosus.","authors":"Eleonora Castellana, Maria Rachele Chiappetta","doi":"10.1177/09612033261458427","DOIUrl":"10.1177/09612033261458427","url":null,"abstract":"<p><p>BackgroundAnifrolumab and belimumab are the two biologic agents currently approved for moderate-to-severe systemic lupus erythematosus (SLE), targeting distinct immunological pathways. While their efficacy has been established in randomized controlled trials, their comparative safety profiles in real-world settings remain incompletely characterized.MethodsA retrospective pharmacovigilance study was conducted using data from the FDA Adverse Event Monitoring System (AEMS) from January 1, 2011 to March 30, 2026. Individual Case Safety Reports (ICSRs) were extracted using \"anifrolumab,\" \"anifrolumab-Fnia,\" and \"belimumab\" as search terms. Adverse drug reactions (ADRs) were coded according to MedDRA version 28.1 Preferred Terms. A disproportionality analysis was performed using the Reporting Odds Ratio (ROR) with 95% confidence intervals; a p-value <0.05 was considered statistically significant.ResultsA total of 2124 ICSRs for anifrolumab and 30,107 for belimumab were identified. Female patients predominated in both groups, consistent with SLE epidemiology. Herpes zoster showed a strong and statistically significant association with anifrolumab (ROR = 5.13; 95% CI: 3.97-6.62; <i>p</i> < 0.0001), consistent with its type I interferon receptor antagonism mechanism. Belimumab was more frequently associated with administration-related events, including missed doses, device misuse, and injection site pain. No statistically significant differences were observed for fatigue, arthralgia, headache, nausea, or rash.ConclusionsAnifrolumab and belimumab exhibit distinct safety profiles. Anifrolumab carries a significantly higher risk of herpes zoster infection, warranting pre-treatment vaccination assessment. Belimumab shows a predominance of administration-related and non-serious events. Treatment selection should be individualized based on patient-specific risk factors, infection susceptibility, and adherence considerations.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"948-955"},"PeriodicalIF":1.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148143953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep immunological resetting in refractory systemic lupus erythematosus post-kidney transplantation: A longitudinal immunophenotypic analysis.","authors":"Ru-Fang Zheng, Jeng-Wei Lu, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Wun-Long Jheng, Feng-Cheng Liu","doi":"10.1177/09612033261458567","DOIUrl":"10.1177/09612033261458567","url":null,"abstract":"<p><p>BackgroundA 66-year-old female with a 15-year history of refractory lupus nephritis, complicated by severe hypersplenism requiring splenectomy and 8 years of hemodialysis, successfully underwent deceased-donor kidney transplantation. Post-transplantation, she achieved an unprecedented, durable serological remission with a distinctive biphasic platelet recovery. MethodsTo monitor her immune reconstitution, we performed longitudinal peripheral blood immunophenotyping, contextualized against an active systemic lupus erythematosus (SLE) cohort and an age-matched healthy control group to account for immunosenescence. ResultsNotably, the B-cell repertoire maintained a persistently stable, low-end baseline of marginal zone B cells within the age-appropriate spectrum, reflecting the static legacy of her prior splenectomy. In sharp contrast to this static background, the T-cell compartment demonstrated a dynamic, within-subject V-shaped recovery of killer cell lectin-like receptor G1 + effector memory cytotoxic T cells (KLRG1 + EM Tc cells) from an active-disease baseline to age-appropriate healthy levels. Conclusions This case illustrates that KLRG1 + effector memory cytotoxic T cell recovery is a signature of genuine immunological remission rather than mere aging or historical confounders, suggesting its potential as a precision biomarker for monitoring post-transplant immune stability in SLE.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"978-982"},"PeriodicalIF":1.8,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148163699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between sarcopenia and lifestyle in patients with systemic lupus erythematosus: A one-institution cross-sectional analysis.","authors":"Qi-Yun Dai, Yoshinari Matsumoto, Chisato Kawakami, Yu-Wei Sun, Masao Katsushima, Ryu Watanabe, Shinsuke Yamada, Daiki Habu, Motomu Hashimoto","doi":"10.1177/09612033261440580","DOIUrl":"10.1177/09612033261440580","url":null,"abstract":"<p><p>BackgroundThis study aimed to investigate the relationships of lifestyle factors, such as diet and physical activity, with sarcopenia in patients with systemic lupus erythematosus (SLE).MethodsA cross-sectional study of clinical immunology outpatients at one medical facility was conducted. Sarcopenia was diagnosed based on the Asian Working Group on Sarcopenia 2019 criteria. Dietary intake was assessed using the brief-type self-administered diet history questionnaire, and physical activity was evaluated with the International Physical Activity Questionnaire. The contribution of dietary factors to sarcopenia was analyzed using logistic regression analysis.ResultsAmong 109 patients (median age 49.5, 83% women), 10 (9.2%) had sarcopenia. The sarcopenia group had significantly lower n-6 fatty acids intake (<i>p</i> = 0.009) and longer sitting time on weekdays (<i>p</i> = 0.033). Logistic regression analysis showed that higher intake of monounsaturated fatty acids [Odds ratio (OR): 0.09, 95% confidence interval (CI): 0.01-0.97], brightly colored vegetables (OR: 0.04, 95% CI: 0.002-0.79), meat (OR: 0.10, 95% CI: 0.01-0.95), and grains (OR: 17.33, 95% CI: 1.09-276.76) were significantly associated with sarcopenia.ConclusionsThis study suggests that dietary factors, such as monounsaturated fatty acids, brightly colored vegetables, meat, and grains, may be associated with sarcopenia in patients with SLE. In addition, the longer sedentary time observed in the sarcopenia group indicates potential for intervention.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"767-778"},"PeriodicalIF":1.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147574756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of anti-DFS70 antibodies in excluding systemic lupus erythematosus diagnosis: An updated systematic review and meta-analysis.","authors":"Yu-Chi Hung, Pao-Feng Hsieh, Kuang-Hui Yu","doi":"10.1177/09612033261442792","DOIUrl":"10.1177/09612033261442792","url":null,"abstract":"<p><p>ObjectivesAnti-dense fine speckled 70 (anti-DFS70) antibodies have been reported to be more prevalent in healthy individuals (HI) than in patients with autoimmune diseases including systemic lupus erythematosus (SLE). However, subsequent studies have yielded inconsistent findings. The reliability of anti-DFS70 antibodies as exclusionary markers for SLE remains uncertain and warrants further investigation.MethodsSixteen studies investigating 6092 subjects (2427 SLE patients and 3665 healthy individuals) were included in the analysis. A meta-analysis was conducted to evaluate and compare the sensitivity, specificity, and diagnostic odds ratio (DOR) of anti-DFS70 antibodies for determining their utility in excluding SLE in the general population.ResultsIn SLE patients, the prevalence of anti-DFS70 antibodies was 10.1% (244/2427; 95% CI: 5.7-14.5%), which was not significantly higher than that of HI, at 5.8% (212/3665; 95% CI: 2.9-8.7%). The pooled sensitivities, specificities, and DOR of anti-DFS70 antibodies for the exclusion of SLE were 0.10 (95% CI: 0.09-0.11), 0.94 (95% CI: 0.93-0.95), 1.04 (95% CI: 0.59-1.85), respectively. The area under the summary receiver operating characteristic (SROC) curve was 0.58 (95% CI: 0.28-0.90), indicating that the test results of anti-DFS70 antibodies have similar distributions in SLE patients and HI. Regarding monospecific anti-DFS70 antibodies in SLE, three studies involving 385 patients with SLE and 648 healthy individuals found these antibodies in 0.8% (3 out of 385) of SLE patients, compared to 6.6% (43 out of 648) of healthy individuals. The corresponding DOR for excluding an SLE diagnosis was 4.00 (95% CI: 1.39-11.46).ConclusionsWhile the present study corroborates findings that the frequency of anti-DFS70 antibodies is slightly higher in SLE patients (10.1%, 244 out of 2427), the lack of statistical significance underscores the need for more comprehensive studies to draw definitive conclusions for the exclusion of SLE.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"800-809"},"PeriodicalIF":1.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147674727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world use of anifrolumab in systemic lupus erythematosus: A retrospective study from a Danish tertiary center (2022-2025).","authors":"Laura Nørgaard, Mads Lamm Larsen, Bent Deleuran, Marie-Louise From Hermansen, Anne Troldborg","doi":"10.1177/09612033261441397","DOIUrl":"10.1177/09612033261441397","url":null,"abstract":"<p><p>ObjectiveTo evaluate the real-world safety, efficacy, and steroid-sparing effects of anifrolumab in patients with systemic lupus erythematosus (SLE) treated at a tertiary referral center in Denmark.MethodsWe conducted a retrospective observational study of all SLE/discoid lupus patients who received at least one infusion of anifrolumab between May 2022 and February 2025 at Aarhus University Hospital. Clinical and laboratory data were extracted from electronic medical records at baseline, 3 months, 6 months, and last follow-up. Disease activity was assessed using SLEDAI-2K, Physician's Global Assessment (PGA), LLDAS, and DORIS criteria.ResultsThirty-six patients (94% female, mean age 52 years) received anifrolumab for a mean of 462 days. Median SLEDAI-2K decreased from 8 at baseline to 2 at month 3, and to 0 at both month 6 and last follow-up. The proportion achieving SLEDAI-2K = 0 increased from 0% at baseline to 52% at both 6 months and last follow-up. At the last follow-up, 87% achieved both PGA ≤0.5 and LLDAS, while 70% achieved DORIS remission. Prednisolone doses declined by >50%. Skin and musculoskeletal involvement showed the greatest improvement. Herpesvirus-related infections were the most frequent adverse events; two severe cases occurred, though treatment was generally continued.ConclusionAnifrolumab was associated with rapid, sustained disease control and significant steroid-sparing effects. Herpesvirus infections were common, underscoring the importance of vaccination prior to treatment initiation. These findings support anifrolumab as an effective therapeutic option for SLE in routine clinical care.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"859-868"},"PeriodicalIF":1.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Childhood systemic lupus erythematosus with lupus myositis: A report of 6 cases.","authors":"Gu Yuxuan, Chen Xin, Chen Zhiguo, Huang Yuchan, Wang Xinlei, Miao Jialei, Liu Ling, Li Chunzhen","doi":"10.1177/09612033261445771","DOIUrl":"10.1177/09612033261445771","url":null,"abstract":"<p><p>ObjectiveTo investigate the clinical characteristics of pediatric systemic lupus erythematosus complicated by myositis.MethodsA retrospective analysis was conducted on the clinical data of six patients with SLE-associated myositis, examining manifestations of multisystem involvement, muscle injury markers, and autoantibody profiles.ResultsAmong the six patients, five were female and one male, with a median age of 12 years. All patients presented with myalgia and/or muscle weakness. Physical examination revealed muscle weakness (grade 2-4) in all six children, with bilateral lower limb myalgia in 4. Laboratory findings showed elevated creatine phosphokinase levels ranging from 217 to 3317 U·L^-1 in four patients. All patients also exhibited elevated lactate dehydrogenase levels, ranging from 293 to 949 U/L. After treatment, clinical symptoms resolved in all patients, with the majority achieving stable conditions. Only one case experienced recurrence due to inappropriate drug tapering, which resolved following readmission and intensive treatment.ConclusionMyositis is not a common feature of SLE. Patients with SLE complicated by myositis should complete relevant investigations at the earliest opportunity. Early diagnosis and stratified individualized treatment can effectively control the disease.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"876-882"},"PeriodicalIF":1.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}